WAT · Earnings call · 2026Q2T · Full report
Acquisition Integration and Synergies
WATERS CORP /DE/ · 2026-08-04 · Importance 69 · Surprise 50 · In source text
The acquired Waters Biosciences and Diagnostic Solutions businesses generated $817 million of second-quarter revenue, up 4% reported year over year. Management raised 2026 acquired-business revenue guidance by $10 million to approximately $3.045 billion, reflecting a $25 million underlying improvement partially offset by $15 million of foreign-exchange pressure. Waters expects $50 million of revenue synergies in 2026 from cross-selling, instrument replacement, service attachment, digital commerce, and pricing. Pricing directors, deal desks, contract-compliance reviews, and China localization are being used to improve commercial execution and recurring revenue.
Key facts
- Expect to deliver $50 million of revenue synergies in 2026
- GAAP diluted loss per share for Q2 2026: $1.39 due to acquisition-related purchase accounting charges including amortization of acquired intangibles and inventory step-up
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Expect to deliver $50 million of revenue synergies in 2026 |